Physician profile
Rahul Khare
NPI 1043248743
$2,811.94
in general payments reported to CMS, 2019-2025
39 companies · $672 in 2025
The $672 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $255 · 2021: $68.29 · 2022: $118 · 2023: $487 · 2024: $512 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $310.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $267.27 | 2021-2025 | |
| Novo Nordisk INC | $227.91 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $192.95 | 2019-2022 | |
| Genentech USA, INC. | $181.72 | 2019-2020 | |
| Gilead Sciences, INC. | $170.06 | 2019 | |
| Exact Sciences Corporation | $162.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $113.70 | 2023-2025 | |
| Viiv Healthcare Company | $109.32 | 2024-2025 | Apretude |
| Glaxosmithkline, LLC. | $93.51 | 2019-2020 | |
| Galderma Laboratories, L.P. | $89.95 | 2022-2023 | |
| Neos Therapeutics, LP | $78.14 | 2019-2023 | Adzenys Xr-Odt |
| Cleerly, INC. | $70.96 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Antares Pharma, INC. | $68.21 | 2025 | Xyosted |
| Corium, LLC | $67.16 | 2023 | Azstarys |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Khare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.